KIMBERLY GERIA: Open Payments
NPI 1801266069 · BRIDGETON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,076 in 32 payments from 12 companies in 2025. Trend: 2023 $148 · 2024 $623 · 2025 $1,076
Food & beverage: $964Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $411 |
| Otsuka America Pharmaceutical, Inc. | 5 | $188 |
| Teva Pharmaceuticals USA, Inc. | 4 | $139 |
| Aimmune Therapeutics, Inc. | 1 | $96 |
| Gilead Sciences, Inc. | 4 | $72 |
| Merck Sharp & Dohme LLC | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
Products named: VRAYLAR, REXULTI, ZENPEP, PIFELTRO, Auvelity, AUSTEDO XR, FANAPT, ARISTADA.
Industry payments across NJ — which companies pay providers there.
